Public Release:  New hope for setback-dogged cancer treatment

Karolinska Institutet

Several drugs companies have ineffectively tried to produce antibodies that bind to the IGF-1 receptor on the cell surface, which has a critical part to play in the development of cancer. Scientists at Karolinska Institutet in Sweden have now ascertained how these antibodies work, and can explain why only some cancer patients are helped by IGF-1 blockers during clinical tests. The researchers also present a means by which drugs of this kind could help more cancer patients.

Every cell contains thousands of tiny receptors that help it communicate with other cells. These receptors are involved in countless physiological processes, such as taste and smell perception and heart rate. A couple of dozen of these receptors form their own family - the kinase receptors (RTKs), which are implicated in cancer. The so-called IGF-1 receptor is particularly important for cancer cell survival, and as soon as this receptor encounters the right hormone (type 1 insulin-like growth factor, or IGF-1) into the cancer cell open a number of communication channels, helping it to grow, rapidly divide and protect itself against treatment.

Blocking this receptor with an antibody that binds to it and makes it inaccessible to IGF-1 has long been regarded as the key to a potential cancer therapy, the idea being that it will eventually lead to the death of the tumour cell. Several drugs companies have therefore been developing such antibodies in order to treat the most aggressive forms of cancer, and after some promising laboratory tests, have tested a number of these preparations on patients. However, the drugs have generally given disappointing results and helped only a small minority of patients (including children with Ewing's sarcoma), leading some companies to discontinue clinical trials focusing on the IGF-1 receptor.

The Karolinska Institutet team has now systematically analysed the different IGF-1-related triggered communication channels within a cancer cell. Their results show that the original idea is correct and that such antibody treatment does actually stop the channels from opening, with one very important exception: the MEK channel was actually powerfully stimulated by the treatment - the antibodies being as effective in this as the hormone itself - and actively helped the cancer cells to survive.

"This gives us a credible explanation why the antibody trials for the IGF-1 receptor weren't as effective as had been hoped," says principal investigator Dr Leonard Girnita, docent of pathology at Karolinska Institutet's Department of Oncology-Pathology. "So it's too early to give up on the idea of treating cancer like this - it's still a very good way of attacking the cancer, provided we can close this final communication channel. If we can do this, antibodies for the IGF-1 receptor are likely to form an effective treatment not only for Ewing's sarcoma in children but many other cancers as well."

Drugs that are used to close this channel in other forms of treatments are already available. The researchers believe that a combination therapy using such MEK inhibitors with IGF-1 blockers can be the key to releasing the potential of this therapy model.

"We've seen in the laboratory that cell lines treated in this way no longer manage to divide," says Dr Girnita. "When they die of old age there is no regrowth, so we've seen in the laboratory environment how cancer cells die out of their own accord."

###

The study was financed with grants from the Swedish Cancer Society, the Swedish Research Council, the Children's Cancer Foundation, the Crown Princess Margareta Fund for the Visually Impaired, the Welander/Finsen foundations, the King Gustaf V Jubilee Fund, Vinnova (The Swedish governmental agency for innovation systems), the Cancer Research Funds of Radiumhemmet, Stockholm County Council and Karolinska Institutet.

Publication: "β-arrestin biased agonism as the central mechanism of action for the IGF-1R targeting antibodies in Ewing's sarcoma", Huiyuan Zheng, Hongchang Shen, Iulian Oprea, Claire Worrall, Radu Stefanescu, Ada Girnita and Leonard Girnita, Proceedings of the National Academy of Sciences (PNAS) online Monday 26 November 2012.

For further information about the study, please contact:
Leonard Girnita, MD, PhD
Associate Professor of Pathology, Group leader
Department of Oncology-Pathology - Karolinska Institutet
Tel: +46 (0)8-517 766 11 or + 46(0)73-6793205
Email: leonard.girnita@ki.se
Website: http://ki.se/ki/jsp/polopoly.jsp?d=24301&l=en

Contact the Press Office and download a photo: ki.se/pressroom

Karolinska Institutet is one of the world's leading medical universities. It accounts for over 40 per cent of the medical academic research conducted in Sweden and offers the country's broadest range of education in medicine and health sciences. Since 1901 the Nobel Assembly at Karolinska Institutet has selected the Nobel laureates in Physiology or Medicine. More on ki.se/english

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.